非霍奇金淋巴瘤的CD20分子显像及靶向治疗研究进展

查林; 冯世斌; 李前伟; 查林; 冯世斌; 李前伟

doi:10.3760/cma.j.issn.1673-4114.2010.05.004

[1]

任金马, 蓝绍颖. 恶性淋巴瘤的流行病学研究进展[J]. 南通医学院学报, 2003, 23(4): 523-525. doi: 10.3969/j.issn.1674-7887.2003.04.122

[2]

刘银星, 杨纯正. CD20分子与靶向治疗[J]. 生命的化学, 2003, 23(1): 60-61. doi: 10.3969/j.issn.1000-1336.2003.01.024

[3]

Du J, Wang H, Zhong C, et al. Structural basis for recognition of CD20 by therapeutic antibody rituximab[J]. J Biol ChemJ Biol Chem, 2007, 282(20): 15073-15080. doi: 10.1074/jbc.M701654200

[4]

Jacobs SA, Foon KA. The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas[J]. Expert Opin Biol TherExpert Opin Biol Ther, 2007, 7(11): 1749-1762. doi: 10.1517/14712598.7.11.1749

[5]

Arzoo K, SadeghiS, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody(rituximab)[J]. Ann Rheum DisAnn Rheum Dis, 2002, 61(10): 922-924. doi: 10.1136/ard.61.10.922

[6]

李禹兵, 刘延香, 路喻清. 非霍奇金淋巴瘤的研究进展[J]. 现代肿瘤医学, 2010, 18(3): 620-624. doi: 10.3969/j.issn.1672-4992.2010.03.077

[7]

Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab[J]. Ann OncolAnn Oncol, 2003, 14(4): 520-535. doi: 10.1093/annonc/mdg175

[8]

Du J, Wang H, Zhong C, et al. Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide[J]. Mol ImmunolMol Immunol, 2008, 45(10): 2861-2868. doi: 10.1016/j.molimm.2008.01.034

[9]

GlennieMJ, French RR, CraggMS, et al. Mechanisms of killing by anti-CD20 monoclonal antibodies[J]. Mol ImmunolMol Immunol, 2007, 44(16): 3823-3837. doi: 10.1016/j.molimm.2007.06.151

[10]

Goldblatt F, Isenberg DA. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus[J]. Handb Exp PharmacolHandb Exp Pharmacol, 2008, 181: 163-181.

[11]

Hayden-Ledbetter MS, Cerveny CG, Espling E, et al. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells[J]. Clin Cancer ResClin Cancer Res, 2009, 15(8): 2739-2746. doi: 10.1158/1078-0432.CCR-08-1694

[12]

Rossi EA, Goldenberg DM, Cardillo TM, et al. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics[J]. Cancer ResCancer Res, 2008, 68(20): 8384-8392. doi: 10.1158/0008-5472.CAN-08-2033

[13]

Leahy MF, Seymour JF, Hicks RJ, et al. Multicenter phase Ⅱ clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma[J]. J Clin OncolJ Clin Oncol, 2006, 24(27): 4418-4425. doi: 10.1200/JCO.2005.05.3470

[14]

Hainsworth JD, Spigel DR, Markus TM, et al. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase IItrial of the Sarah Cannon Oncology Research Consortium[J]. Clin Lymphoma MyelomaClin Lymphoma Myeloma, 2009, 9(3): 223-228. doi: 10.3816/CLM.2009.n.044

[15]

Forrer F, Chen J, FaniM, et al. In vitro characterization of¹⁷⁷Luradiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study[J]. Eur J Nucl Med and Mol ImagingEur J Nucl Med and Mol Imaging, 2009, 36(9): 1443-1452. doi: 10.1007/s00259-009-1120-2

[16]

Beyer GJ, Miederer M, Vranjes-Duri S, et al. Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using ¹⁴⁹Tb-rituximab[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2004, 31(4): 547-554. doi: 10.1007/s00259-003-1413-9

[17]

Cronin CG, SwordsR, TruongMT, et al. Clinicalutility of PET/CT in lymphoma[J]. AJR Am J RoentgenolAJR Am J Roentgenol, 2010, 194(1): W91-W103.

[18]

Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma[J]. J Nucl MedJ Nucl Med, 2009, 50(Suppl1): 21S-30S.

[19]

Juweid ME. Utility of positron emission tomography(PET)scanning in managing patients with Hodgkin lymphoma[J]. Hematology Am Soc Hematol Educ ProgramHematology Am Soc Hematol Educ Program, 2006, 501(1): 259-265.

[20]

Kazama T, Faria SC, Varavithya V, et al. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls[J]. RadiographicsRadiographics, 2005, 25(1): 191-207. doi: 10.1148/rg.251045045

[21]

Stopar TG, Mlinaric-Rascan I, Fettich J, et al. ^99mTc-rituximab radiolabelled by photo-activation: a new non-Hodgkin's lymphoma imaging agent[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2006, 33(1): 53-59. doi: 10.1007/s00259-005-1838-4

[22]

Gmeiner Stopar T, Fettich J, Zver S, et al. ^99mTc-labelled rituximab, a new non-Hodgkin's lymphoma imaging agent: first clinical experience[J]. Nucl Med CommunNucl Med Commun, 2008, 29(12): 1059-1065.

[23]

Olafsen T, Betting D, Kenanova VE, et al. Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas[J]. J Nucl MedJ Nucl Med, 2009, 50(9): 1500-1508.

[24]

Olafsen T, Sirk SJ, Betting DJ, et al. ImmunoPET imaging of B-cell lymphoma using ¹²⁴Ⅰ-anti-CD20 scFv dimers(diabodies)[J]. Protein Eng, Des SelProtein Eng, Des Sel, 2010, 23(4): 243-249. doi: 10.1093/protein/gzp081

[1]	任金马, 蓝绍颖. 恶性淋巴瘤的流行病学研究进展[J]. 南通医学院学报南通医学院学报, 2003, 23(4): 523-525. doi: 10.3969/j.issn.1674-7887.2003.04.122
[2]	刘银星, 杨纯正. CD20分子与靶向治疗[J]. 生命的化学生命的化学, 2003, 23(1): 60-61. doi: 10.3969/j.issn.1000-1336.2003.01.024
[3]	Du J, Wang H, Zhong C, et al. Structural basis for recognition of CD20 by therapeutic antibody rituximab[J]. J Biol ChemJ Biol Chem, 2007, 282(20): 15073-15080. doi: 10.1074/jbc.M701654200
[4]	Jacobs SA, Foon KA. The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas[J]. Expert Opin Biol TherExpert Opin Biol Ther, 2007, 7(11): 1749-1762. doi: 10.1517/14712598.7.11.1749
[5]	Arzoo K, SadeghiS, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody(rituximab)[J]. Ann Rheum DisAnn Rheum Dis, 2002, 61(10): 922-924. doi: 10.1136/ard.61.10.922
[6]	李禹兵, 刘延香, 路喻清. 非霍奇金淋巴瘤的研究进展[J]. 现代肿瘤医学现代肿瘤医学, 2010, 18(3): 620-624. doi: 10.3969/j.issn.1672-4992.2010.03.077
[7]	Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab[J]. Ann OncolAnn Oncol, 2003, 14(4): 520-535. doi: 10.1093/annonc/mdg175
[8]	Du J, Wang H, Zhong C, et al. Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide[J]. Mol ImmunolMol Immunol, 2008, 45(10): 2861-2868. doi: 10.1016/j.molimm.2008.01.034
[9]	GlennieMJ, French RR, CraggMS, et al. Mechanisms of killing by anti-CD20 monoclonal antibodies[J]. Mol ImmunolMol Immunol, 2007, 44(16): 3823-3837. doi: 10.1016/j.molimm.2007.06.151
[10]	Goldblatt F, Isenberg DA. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus[J]. Handb Exp PharmacolHandb Exp Pharmacol, 2008, 181: 163-181.
[11]	Hayden-Ledbetter MS, Cerveny CG, Espling E, et al. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells[J]. Clin Cancer ResClin Cancer Res, 2009, 15(8): 2739-2746. doi: 10.1158/1078-0432.CCR-08-1694
[12]	Rossi EA, Goldenberg DM, Cardillo TM, et al. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics[J]. Cancer ResCancer Res, 2008, 68(20): 8384-8392. doi: 10.1158/0008-5472.CAN-08-2033
[13]	Leahy MF, Seymour JF, Hicks RJ, et al. Multicenter phase Ⅱ clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma[J]. J Clin OncolJ Clin Oncol, 2006, 24(27): 4418-4425. doi: 10.1200/JCO.2005.05.3470
[14]	Hainsworth JD, Spigel DR, Markus TM, et al. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase IItrial of the Sarah Cannon Oncology Research Consortium[J]. Clin Lymphoma MyelomaClin Lymphoma Myeloma, 2009, 9(3): 223-228. doi: 10.3816/CLM.2009.n.044
[15]	Forrer F, Chen J, FaniM, et al. In vitro characterization of¹⁷⁷Luradiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study[J]. Eur J Nucl Med and Mol ImagingEur J Nucl Med and Mol Imaging, 2009, 36(9): 1443-1452. doi: 10.1007/s00259-009-1120-2
[16]	Beyer GJ, Miederer M, Vranjes-Duri S, et al. Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using ¹⁴⁹Tb-rituximab[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2004, 31(4): 547-554. doi: 10.1007/s00259-003-1413-9
[17]	Cronin CG, SwordsR, TruongMT, et al. Clinicalutility of PET/CT in lymphoma[J]. AJR Am J RoentgenolAJR Am J Roentgenol, 2010, 194(1): W91-W103.
[18]	Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma[J]. J Nucl MedJ Nucl Med, 2009, 50(Suppl1): 21S-30S.
[19]	Juweid ME. Utility of positron emission tomography(PET)scanning in managing patients with Hodgkin lymphoma[J]. Hematology Am Soc Hematol Educ ProgramHematology Am Soc Hematol Educ Program, 2006, 501(1): 259-265.
[20]	Kazama T, Faria SC, Varavithya V, et al. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls[J]. RadiographicsRadiographics, 2005, 25(1): 191-207. doi: 10.1148/rg.251045045
[21]	Stopar TG, Mlinaric-Rascan I, Fettich J, et al. ^99mTc-rituximab radiolabelled by photo-activation: a new non-Hodgkin's lymphoma imaging agent[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2006, 33(1): 53-59. doi: 10.1007/s00259-005-1838-4
[22]	Gmeiner Stopar T, Fettich J, Zver S, et al. ^99mTc-labelled rituximab, a new non-Hodgkin's lymphoma imaging agent: first clinical experience[J]. Nucl Med CommunNucl Med Commun, 2008, 29(12): 1059-1065.
[23]	Olafsen T, Betting D, Kenanova VE, et al. Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas[J]. J Nucl MedJ Nucl Med, 2009, 50(9): 1500-1508.
[24]	Olafsen T, Sirk SJ, Betting DJ, et al. ImmunoPET imaging of B-cell lymphoma using ¹²⁴Ⅰ-anti-CD20 scFv dimers(diabodies)[J]. Protein Eng, Des SelProtein Eng, Des Sel, 2010, 23(4): 243-249. doi: 10.1093/protein/gzp081